- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05054790
Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct
November 30, 2023 updated by: Wake Forest University Health Sciences
A Phase 2 Study of Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct In Subjects With Fibrotic Contracted Bladder
The purpose of this research study is to find out if autologous "neo-bladder" construct for the treatment of fibrotic and/or contracted bladder can improve bladder compliance and be safe long term.
The neo-bladder is like a reservoir or pouch that will be surgically attached to the bladder to assist with urine collection.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, open-label, single-group clinical study.
All subjects will have non-neurogenic, fibrotic contracted bladder that is refractory to medical treatment and require augmentation cystoplasty for preventing long-term sequelae (i.e., kidney failure) that result from persistently high intravesical pressure.
Subjects will undergo an open full thickness bladder biopsy from which autologous urinary bladder smooth muscle and urothelial cells will be procured and expanded ex vivo.
After approximately 5 - 7 weeks, expanded cells will be seeded on a biodegradable scaffold to produce the neo-bladder construct that will be surgically implanted onto an opened native bladder during an augmentation cystoplasty.
Subjects will be followed for 36 months.
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mary-Clare Day, RN, BSN
- Phone Number: 336-713-1343
- Email: mday@wakehealth.edu
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Atrium Health Wake Forest Baptist
-
Contact:
- Mary-Clare Day, RN, BSN
- Phone Number: 336-713-1343
- Email: mday@wakehealth.edu
-
Principal Investigator:
- Robert J Evans, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 58 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects with small contracted and/or fibrotic non-neurogenic bladder.
- Small bladder <150cc capacity
- Willing and able to give signed informed consent in English.
- Ability of subject to be successfully trained in clean intermittent catheterization and bladder cycling
- Failure to respond to maximum approve dose of medical therapy (e.g. anticholinergics) or failure to tolerate /contraindication to such agents
Medical need for bladder augmentation, as defined by the presence of:
- Decreased and inadequate bladder compliance with a bladder pressure ≥40 cmH20. OR
- New-onset of upper urinary tract changes (hydronephrosis, vesicoureteral reflux) in the last 12 months
Exclusion:
- Neurogenic bladder
- Recent (< 12 months) urological or intraperitoneal surgery or device implantation; recent (<6 month neurologic surgery-brain or spine)
- Any prior bladder augmentation procedure
- Known or suspected limitation to obtaining omentum for implantation procedure (e.g., extensive intraperitoneal adhesions)
- Any contraindication to general anesthesia
- Any contraindication or known anaphylactic or severe systemic reaction to either human blood products or materials of bovine origin
- Human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), active hepatitis A (HAV) or other known active infection
- Subjects with active tuberculosis (TB) requiring treatment in the past 3 years. Subjects with a current positive (≥5 mm induration for high-risk subjects; otherwise ≥10 mm of induration) purified protein derivative (PPD) test are excluded unless they have completed a full course of treatment for latent TB and have a negative chest x-ray film at enrollment.
- Subjects known to be colonized with either methicillin-resistant staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE), or gentamicin-resistant organisms.
- Receipt of blood or blood products for transfusion during the 3 months prior to biopsy
- Immunocompromised subjects or subjects receiving immunosuppressive agents (inhaled corticosteroids and chronic low-dose corticosteroids [≤0.25 mg/kg prednisone or equivalent per day] are permitted).
- Brief pulsed corticosteroids for intermittent symptoms (e.g., asthma) are permitted.
- Known history of hypersensitivity to aminoglycosides or fluoroquinolones.
- History of true allergy to iodine or iodinated x-ray contrast agents
- Use of any investigational product within 3 months
- Prior participation in the study
- Any history of alcohol and/or any drug abuse
- Current incarceration for any reason
- Unwillingness, inability, or unlikely compliance with study related procedures
- Any circumstance in which the investigator deems participation in the study is not in the subject's best interest
- Subjects with an Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) value >3 times the upper limit of normal
- Subjects with an albumin value <3.0 g/dL
- Subjects with a history of an anaphylactic or a severe systemic reaction to the biodegradable polymers glycolic acid (PGA) and lactic-co-glycolic acid (PLGA)
- Subjects with acute or chronic abdominal skin infections and/or acute or chronic inflammatory bowel disease
- Subjects with uncontrolled diabetes, unstable cardiac and/or pulmonary disorders, or bleeding disorders
- Subjects who have received Botulinum Toxin A injections into the bladder within the previous 12 months.
- Female subjects who are pregnant, planning to get pregnant or lactating/breast-feeding.
Female subjects of child-bearing potential unwilling to practice an effective method of birth control as determined by the investigator (e.g., oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or partner with vasectomy) for duration of the study.
- If a patient has had a hysterectomy, a bilateral oophorectomy, documented ovarian failure or is older than age 51.5 years and has not had a menstrual period in more than 12 months, they will be considered to be non-childbearing. This will be ascertained from patient interview/self-report, medical records (if necessary) and the investigator's judgment. "Spontaneous menopause," occurs in the United States at a mean age of 51.5 years.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous "Neo-Bladder" Construct
All subjects enrolled will have non-neurogenic, fibrotic contracted bladder that is refractory to medical treatment and require augmentation cystoplasty for preventing long-term sequelae (i.e., kidney failure) that result from persistently high intravesical pressure.
|
Subjects will undergo an open full thickness bladder biopsy from which autologous urinary bladder smooth muscle and urothelial cells will be procured and expanded ex vivo.
After approximately 5 - 7 weeks, expanded cells will be seeded on a biodegradable scaffold to produce the neo-bladder construct that will be surgically implanted onto an opened native bladder during an augmentation cystoplasty.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bladder Compliance Average
Time Frame: Month 12
|
Average bladder capacity as found on Urodynamics results
|
Month 12
|
Average Number of 24 Hour Voids
Time Frame: Month 6
|
Per voiding diary
|
Month 6
|
Average Number of 24 Hour Voids
Time Frame: Month 9
|
Per voiding diary
|
Month 9
|
Average Number of 24 Hour Voids
Time Frame: Month 12
|
Per voiding diary
|
Month 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Bladder Capacity
Time Frame: From Baseline through Month 12
|
Shown through urodynamics study
|
From Baseline through Month 12
|
End filling pressure
Time Frame: Baseline, Month 6, Month 9 and Month 12
|
At age-related nomogram-derived bladder capacity
|
Baseline, Month 6, Month 9 and Month 12
|
Urogenital Distress Inventory-6 Question (UDI-6)
Time Frame: Month 6, Month 9 and Month 12
|
Evaluation of urogenital function from self-reported questionnaire.
Score ranges from 0-18 with higher score denoting worsening in urogenital function.
|
Month 6, Month 9 and Month 12
|
Urogenital Distress Inventory-7 Question (UDI-7)
Time Frame: Month 6, Month 9 and Month 12
|
Evaluation of urogenital function from self-reported questionnaire.
Score ranges from 0-21 with higher score denoting worsening in urogenital function.
|
Month 6, Month 9 and Month 12
|
Genitourinary Pain Index (GUPI)
Time Frame: Month 6, Month 9 and Month 12
|
Evaluation of pain from self-reported questionnaire.
Score ranges from 0-45 with a higher score denoting worse symptoms.
|
Month 6, Month 9 and Month 12
|
Quality of Life (QOL) Questionnaire
Time Frame: Month 6, Month 9 and Month 12
|
Self-reported quality of life evaluation.
Score ranges from 0-6 with highest score denoting the worst feelings about quality of life.
|
Month 6, Month 9 and Month 12
|
American Urological Association Symptom Score (AUASS)
Time Frame: Month 6, Month 9 and Month 12
|
Self-reported urological symptom assesment.
Score ranges from 1-35 with score of 1-7 denoting mild symptoms, 8-19 denoting moderate symptoms and 20-35 denoting severe symptoms.
|
Month 6, Month 9 and Month 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Robert J. Evans, MD, Atrium Health Wake Forest Baptist
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2024
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
September 14, 2021
First Submitted That Met QC Criteria
September 14, 2021
First Posted (Actual)
September 23, 2021
Study Record Updates
Last Update Posted (Estimated)
December 4, 2023
Last Update Submitted That Met QC Criteria
November 30, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- IRB00076977
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contracted Bladder
-
Sheba Medical CenterUnknown
-
Peking University First HospitalRecruitingUrinary Bladder Cancer | Bladder Cancer | Bladder Neoplasms | Bladder Tumors | Neoplasms, BladderChina
-
Novartis PharmaceuticalsTerminatedNeurogenic Urinary Bladder | Neurogenic Bladder Disorder | Neurogenic Dysfunction of the Urinary Bladder | Neurogenic Bladder, Uninhibited | Neurogenic Bladder, SpasticNetherlands, Germany, Switzerland
-
Mansoura UniversityCompletedBladder Cancer | Bladder Disease | Bladder Neoplasm | Micro-RNAEgypt
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Medical Enterprises Ltd.TerminatedUrinary Bladder Cancer | Bladder Cancer | Malignant Tumor of Urinary Bladder | Bladder Neoplasm | Cancer of Bladder | Carcinoma in Situ of Bladder | Bladder Tumors | Cancer of the Bladder | Neoplasms, Bladder | Papillary Carcinoma of Bladder (Diagnosis) | BCG-Unresponsive Bladder CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
Stanford UniversityAstraZenecaTerminatedBladder Adenocarcinoma | Bladder Mixed Adenocarcinoma | Bladder Squamous Cell Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Giant Cells | Infiltrating Bladder Urothelial Carcinoma, Nested Variant | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Bladder Urothelial... and other conditionsUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
Clinical Trials on "Neo-Bladder" Construct
-
TengionTerminated
-
University of BarcelonaUniversitat Oberta de CatalunyaActive, not recruiting
-
Boston Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); Children's Hospital Medical...Completed
-
TengionWithdrawnOveractive BladderUnited States
-
TengionTerminatedNeurogenic BladderUnited States
-
Wake Forest University Health SciencesRecruitingCongenital Mullerian Duct AnomalyUnited States
-
Wake Forest University Health SciencesUnited States Department of DefenseNot yet recruitingUrologic Diseases | Male Urogenital Diseases | Urethral Stricture | Urethral InjuryUnited States
-
Red de Terapia CelularFundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia and other collaboratorsUnknown
-
Orlando Health, Inc.TerminatedArthritis | Joint DiseasesUnited States
-
I.M. Sechenov First Moscow State Medical UniversityUnknownUrethral StrictureRussian Federation